Related references
Note: Only part of the references are listed.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
Nicholas M. Levinson et al.
PLOS ONE (2012)
Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
G. Vignir Helgason et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
L. L. Remsing Rix et al.
LEUKEMIA (2009)
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Artur Gontarewicz et al.
BLOOD (2008)
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
Michael Brave et al.
CLINICAL CANCER RESEARCH (2008)
Exploitation of the 3-quinolinecarbonitrile template for Src tyrosine kinase inhibitors
Diane H. Boschelli
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2008)
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check
Thomas O'Hare et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Homoharringtonine for the treatment of chronic myelogenous leukemia
Alfonso Quintas-Cardama et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
Shaoguang Li
LEUKEMIA & LYMPHOMA (2008)
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
Heiko Konig et al.
BLOOD (2008)
Src family nonreceptor tyrosine kinases as molecular targets for cancer therapy
Faye M. Johnson et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606
Manuela Mancini et al.
LEUKEMIA RESEARCH (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Inhibitory effect of imatinib on normal progenitor cells in vitro
K Bartolovic et al.
BLOOD (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells
A Ptasznik et al.
NATURE MEDICINE (2004)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
Practical management of patients with chronic myeloid leukemia receiving imatinib
MWN Deininger et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Src family kinases in tumor progression and metastasis
JM Summy et al.
CANCER AND METASTASIS REVIEWS (2003)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
DH Boschelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Share Paper
